<DOC>
	<DOCNO>NCT02483000</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose anti-cluster differentiation ( CD ) 20 radioimmunotherapy ( RIT ) , see well work give chemotherapy stem cell transplant treat patient B-cell malignancy respond treatment come back respond treatment . CD20 protein find cell type cancer cell call B-cells . Anti-CD20 RIT attach radioactive material drug design target CD20 , bring radioactive material cancer cell kill cell . This may kill tumor cell cause few side effect healthy tissue . Adding anti-CD20 standard chemotherapy stem cell transplant may effective treat patient B-cell malignancy .</brief_summary>
	<brief_title>Anti-CD20 Radioimmunotherapy Before Chemotherapy Stem Cell Transplant Treating Patients With High-Risk B-Cell Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) 90Y activity deliver via pretargeted radioimmunotherapy ( PRIT ) use B9E9-fusion protein ( B9E9-FP ) , clear agent ( CA ) , radiolabeled DOTA-biotin follow carmustine , etoposide , cytarabine , melphalan ( BEAM ) chemotherapy autologous stem cell transplantation . SECONDARY OBJECTIVES : I . To assess overall progression-free survival regimen patient . II . To evaluate response rate therapy . III . To evaluate toxicity tolerability therapy . IV . To evaluate feasibility deliver sequential high-dose PRIT chemotherapy . TERTIARY OBJECTIVES : I. Assess biodistribution pharmacokinetics B9E9-FP radiolabeled DOTA-Biotin . II . Assess ability clearing agent ( CA ) remove excess B9E9-FP serum . III . Evaluate impact , , circulate rituximab biodistributions . OUTLINE : This phase I , dose-escalation study yttrium Y 90 DOTA-biotin follow phase II study . B9E9-FP INFUSION : Patients receive B9E9-fusion protein intravenously ( IV ) minimum 2 hour day -17 . CLEARING AGENT INFUSION : Patients receive clear agent IV minimum 30 minute day -15 . RADIOBIOTIN INFUSION : Patients receive indium In 111-DOTA-biotin IV yttrium Y 90 DOTA-biotin IV 2-5 minute day -14 . BEAM CHEMOTHERAPY : Patients receive BEAM chemotherapy comprise carmustine IV 3 hour day -7 ; etoposide IV 2 hour twice daily ( BID ) cytarabine IV 4 hour BID day -6 -3 ; melphalan IV 30 minute day -2 . STEM CELL INFUSION : Patients undergo autologous peripheral blood stem cell transplant ( PBSCT ) day 0 per standard care . After completion study treatment , patient follow 1 , 3 , 6 , 12 month , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>Patients must histologically confirm diagnosis lymphoma express CD20 antigen generally must fail least one prior standard systemic therapy ; exception mantle cell lymphoma ( MCL ) patient , may enrol first complete remission ( CR ) well select highrisk lymphoma ( e.g. , Burkitt 's , double hit diffuse large Bcell lymphoma [ DLBCL ] , transform indolent Bcell nonHodgkin lymphoma [ BNHL ] , etc . ) accordance current transplant standard care patient Creatinine ( Cr ) &lt; 2.0 Bilirubin &lt; 1.5 mg/dL , exception patient think Gilbert 's syndrome , may total bilirubin 1.5 mg/dL All patient eligible therapeutic study must ( &gt; = 2 x 10^6 CD34/kg ) autologous hematopoietic stem cell harvest cryopreserved Patients must expect survival &gt; 60 day must free major infection Patients childbearing potential must agree abstinence use effective contraception DONOR SELECTION : Not applicable ; protocol employ autologous transplantation , utilize patient 's hematopoietic stem cell obtain either peripheral blood bone marrow Systemic antilymphoma therapy give previous 30 day schedule 90Y therapy dose Inability understand give inform consent Prior radiation &gt; 20 Gy critical normal organ ( e.g. , lung , liver , spinal cord , kidney ) within 1 year treatment date Active central nervous system lymphoma Other serious medical condition consider represent contraindication bone marrow transplant ( BMT ) ( e.g. , abnormally decreased cardiac ejection fraction , diffusion capacity lung carbon monoxide [ DLCO ] &lt; 50 % predict , patient supplemental oxygen , acquire immune deficiency syndrome [ AIDS ] , etc . ) Pregnancy breast feed Prior bone marrow stem cell transplant Southwest Oncology Group ( SWOG ) performance status &gt; = 2.0 Known sensitivity kanamycin aminoglycosides ; patient know hypersensitivity kanamycin aminoglycoside antibiotic exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>